Index Catalog // ScholarsArchive@OSU

Creator:: Hartung, Daniel M., Bourdette, Dennis N., Ahmed, Sharia M., and Whitham, Ruth H.
Abstract:: Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices. Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to...
Resource Type:: Article

Creator:: Hartung, Daniel M., Bourdette, Dennis N., Ahmed, Sharia M., and Whitham, Ruth H.
Abstract:: Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices. Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to...
Full Text:: toward a cure for MS is hampered because it would affect profits. Author Response: Daniel M. Hartung

Creator:: Hartung, Daniel M., Bourdette, Dennis N., Ahmed, Sharia M., and Whitham, Ruth H.
Abstract:: Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices. Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to...
Full Text:: ISSUES Daniel M. Hartung, PharmD, MPH Dennis N. Bourdette, MD Sharia M. Ahmed, MPH Ruth H. Whitham, MD

Creator:: Hartung, Daniel M., Bourdette, Dennis N., Ahmed, Sharia M., and Whitham, Ruth H.
Abstract:: Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices. Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to...
Full Text:: page 9 2 Investigators Daniel M. Hartung, PharmD, MPH1*; Dennis N. Bourdette, MD

Creator:: Evans, David, Hartung, Daniel M., Beasley, Denise, and Fagnan, Lyle J.
Abstract:: Background: Academic medical centers are examining relationships with the pharmaceutical industry and making changes to limit interactions. Most doctors, however, practice outside of academic institutions and see pharmaceutical detailers and accept drug samples and gifts. Little guidance for practicing physicians exists about transforming practices to become pharma-free. Consideration must be...
Resource Type:: Article
Full Text:: from a Pharma-Free Practice Transformation David Evans, MD, Daniel M. Hartung, PharmD, MPH, Denise

Creator:: Hartung, Daniel M., Middleton, Luke, Markwardt, Sheila, Williamson, Kaylee, and Ketchum, Kathy
Abstract:: PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma. The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization. METHODS: Using administrative data...
Full Text:: FDA’s 2010 Drug Safety Communication Hartung, D. M., Middleton, L., Markwardt, S., Williamson, K

Creator:: Hartung, Daniel M., Bourdette, Dennis N., Ahmed, Sharia M., and Whitham, Ruth H.
Abstract:: Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices. Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to...

Creator:: Hartung, Daniel M., Middleton, Luke, Markwardt, Sheila, Williamson, Kaylee, and Ketchum, Kathy
Abstract:: PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma. The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization. METHODS: Using administrative data...

Creator:: Hartung, Daniel M., Middleton, Luke, Markwardt, Sheila, Williamson, Kaylee, and Ketchum, Kathy
Abstract:: PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma. The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization. METHODS: Using administrative data...

ScholarsArchive@OSU